Literature DB >> 18419491

The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals.

Keith S Kaye1, Deverick J Anderson, Yong Choi, Katherine Link, Paul Thacker, Daniel J Sexton.   

Abstract

INTRODUCTION: Data regarding the epidemiology, treatment, and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) infections in rural and community hospitals are limited.
METHODS: This cohort study was conducted at 1 tertiary care hospital and 8 community hospitals in the southeastern United States. Patients with a surgical site infection (SSI) and/or bacteremia due to MRSA were prospectively identified at each study hospital during the period 1994-2003.
RESULTS: A total of 129 patients with SSI and 564 patients with bacteremia due to MRSA were identified. Only 57 patients with SSI (44.2%) received antibiotics active against MRSA on the initial date of diagnosis; only 95 (73.6%) received an agent active against MRSA by day 7 after diagnosis of SSI due to MRSA. Ninety-five patients with SSI due to MRSA (73.6%) were readmitted to the hospital within 90 days after their original surgery. The 1-year mortality rate among patients with SSI due to MRSA was 22%. Inadequate therapy was also commonly given to patients with bacteremia: only 216 (38.3%) received antibiotics active against MRSA on the initial day of infection, and only 383 (67.9%) received an agent active against MRSA by day 7 after diagnosis. Approximately one-third of patients with bloodstream infection died during their initial hospitalization. Patients hospitalized in community hospitals were less likely to receive effective antimicrobial therapy on both the day of infection and within 7 days after infection, compared with patients in the tertiary care hospital.
CONCLUSION: Inadequate therapy is commonly administered after diagnosis of SSI and bacteremia due to MRSA in patients in community hospitals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419491     DOI: 10.1086/587673

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Meta-analysis of methicillin-resistant Staphylococcus aureus colonization and risk of infection in dialysis patients.

Authors:  Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

2.  Antimicrobial stewardship as part of the infection prevention effort.

Authors:  Rebekah W Moehring; Deverick J Anderson
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

3.  Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.

Authors:  John A Bosso; Jean Nappi; Celeste Rudisill; Marlea Wellein; P Brandon Bookstaver; Jenna Swindler; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections.

Authors:  Andrew S Lubin; David R Snydman; Robin Ruthazer; Pralhad Bide; Yoav Golan
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

5.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

6.  Surgical site infection prophylaxis strategies for cardiothoracic surgery: a decision-analytic model.

Authors:  Keith S Kaye; Scott T Devine; Kimbal D Ford; Deverick J Anderson
Journal:  Scand J Infect Dis       Date:  2012-07-25

7.  Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA.

Authors:  Jingru Meng; Hui Wang; Zheng Hou; Tao Chen; Jingguo Fu; Xue Ma; Gonghao He; Xiaoyan Xue; Min Jia; Xiaoxing Luo
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

8.  Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.

Authors:  Avanish K Varshney; Xiaobo Wang; Matthew D Scharff; Jennifer MacIntyre; Richard S Zollner; Oleg V Kovalenko; Luis R Martinez; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

9.  Disinfection and healing effects of 222-nm UVC light on methicillin-resistant Staphylococcus aureus infection in mouse wounds.

Authors:  Kouji Narita; Krisana Asano; Yukihiro Morimoto; Tatsushi Igarashi; Michael R Hamblin; Tianhong Dai; Akio Nakane
Journal:  J Photochem Photobiol B       Date:  2017-10-27       Impact factor: 6.252

10.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.